GlassScriptPhysician profile
Jian Zhao
NPI 1265660179
$2,204.18
in general payments reported to CMS, 2019-2025
19 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $78.21 · 2023: $440 · 2024: $610 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $392.74 | 2023-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $281.72 | 2023-2025 | Synthroid |
| Boston Scientific Corporation | $250.17 | 2023-2024 | Intracept, Watchman Flx |
| Lilly USA, LLC | $232.25 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $202.16 | 2023-2025 | Rybelsus, Ozempic, Tresiba |
| Glaxosmithkline, LLC. | $173.92 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $145.79 | 2022-2025 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $143.93 | 2023-2025 | |
| Exact Sciences Corporation | $70.64 | 2024-2025 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $61.99 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.31 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $39.21 | 2025 | |
| Shield Therapeutics INC | $29.92 | 2023-2024 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $25.99 | 2022-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $24.47 | 2023 | Rexulti, Abilify Asimtufii |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.35 | 2024 | |
| Astellas Pharma US INC | $21.64 | 2024 | Veozah |
| Esperion Therapeutics, INC. | $17.29 | 2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $14.69 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jian Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.